SB
SBMFF.US Sino Biopharmaceutical Limited
- Market cap
- USD 11.8B
- P/E
- 33.3x
- P/B
- 2.42x
- ROE
- 21.1%
- Dividend yield
- 2.30%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is SBMFF.US undervalued?
Graham numberSBMFF.US trades 89.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sino Biopharmaceutical Limited fundamental analysis
No fundamental analysis for Sino Biopharmaceutical Limited yet.
Sino Biopharmaceutical Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, ben…
Full company profileSino Biopharmaceutical Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sino Biopharmaceutical Limited annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 14.2B | 14.8B | 20.9B | 24.2B | 23.6B | 26.9B | 26.0B | 26.2B | 28.9B | 31.0B | 38.9B |
| Gross Profit | 11.2B | 11.7B | 16.7B | 19.3B | 18.5B | 21.5B | 21.5B | 21.2B | 23.5B | 25.5B | 32.3B |
| Operating Income | 4.71B | 4.17B | 4.97B | 5.81B | 4.19B | 5.08B | 5.59B | 5.79B | 6.14B | 6.64B | 13.7B |
| EBITDA | 3.60B | 4.62B | 6.15B | 7.37B | 5.75B | 19.9B | 6.69B | 6.98B | 6.49B | 7.85B | 14.3B |
| Net Income | 1.71B | 2.17B | 9.05B | 4.69B | 2.77B | 14.6B | 2.54B | 2.33B | 3.50B | 2.28B | 6.87B |
| EPS | 0.10 | 0.13 | 0.49 | 0.25 | 0.15 | 0.76 | 0.13 | 0.13 | 0.19 | 0.13 | 0.38 |
| Balance Sheet | |||||||||||
| Total Assets | 18.4B | 20.9B | 49.8B | 58.3B | 47.2B | 60.5B | 64.1B | 63.6B | 65.4B | 76.0B | 83.2B |
| Total Liabilities | 7.70B | 8.32B | 12.2B | 18.0B | 24.8B | 22.8B | 26.1B | 25.4B | 22.6B | 33.3B | 37.0B |
| Shareholders' Equity | 7.96B | 9.21B | 29.2B | 31.1B | 16.7B | 30.3B | 29.7B | 30.5B | 32.0B | 30.7B | 32.6B |
| Cash & Short-term Investments | 8.57B | 9.90B | 13.0B | 19.1B | 16.4B | 15.8B | 16.9B | 14.1B | 14.6B | 23.0B | 27.6B |
| Total Debt | 3.05B | 2.95B | 3.41B | 8.62B | 14.2B | 12.1B | 14.0B | 12.6B | 9.78B | 16.1B | 17.2B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.09B | 3.73B | 5.09B | 5.32B | 5.33B | 5.37B | 6.27B | 6.07B | 6.62B | 9.29B | - |
| Capital Expenditure | 935M | 1.46B | 1.69B | 1.73B | 1.86B | 1.89B | 1.71B | 1.70B | 960M | 1.70B | 0.00 |
| Free Cash Flow | 2.16B | 2.27B | 3.40B | 3.59B | 3.47B | 3.47B | 4.56B | 4.36B | 5.66B | 7.59B | - |
| Ratios | |||||||||||
| ROE | 21.5% | 23.6% | 31.0% | 15.1% | 16.5% | 48.2% | 8.6% | 7.7% | 11.0% | 7.4% | 21.1% |
| ROA | 9.3% | 10.4% | 18.2% | 8.1% | 5.9% | 24.1% | 4.0% | 3.7% | 5.4% | 3.0% | 8.3% |
| Net Profit Margin | 12.1% | 14.6% | 43.3% | 19.4% | 11.7% | 54.4% | 9.8% | 8.9% | 12.1% | 7.4% | 17.7% |
| Debt to Equity | 0.38x | 0.32x | 0.12x | 0.28x | 0.85x | 0.40x | 0.47x | 0.41x | 0.31x | 0.52x | 0.53x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sino Biopharmaceutical Limited dividends
- Dividend yield
- 2.30%
- Forward dividend
- 0.02 USD
- Payout ratio
- 65.8%
- Ex-dividend date
- Sep 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.50B | 0.08 | 65.8% |
| 2024 | CNY 1.85B | 0.10 | 52.8% |
| 2023 | CNY 633M | 0.03 | 27.1% |
| 2022 | CNY 1.27B | 0.07 | 49.8% |
| 2021 | USD 938M | 0.05 | 6.4% |
| 2020 | USD 1.19B | 0.06 | 42.8% |
| 2019 | USD 820M | 0.04 | 17.5% |
| 2018 | USD 710M | 0.04 | 7.9% |
| 2017 | CNY 450M | 0.03 | 20.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:2 on Jun 4, 2018.
Who owns Sino Biopharmaceutical Limited
- Insiders 48.66%
- Institutions 23.09%
- Public & others 28.25%
- Shares outstanding 17.8B
- Free float 8.73B
Sino Biopharmaceutical Limited company profile
- Company name
- Sino Biopharmaceutical Limited
- Ticker
- SBMFF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 22,838
- Fiscal year end
- December
- Address
- Unit 09, Office Tower, Wan Chai, Hong Kong
- Phone
- 852 2802 9886
- Website
- sbpgroup.com
About Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, culmerciclib capsule under Saitanxin brand, zongertinib tablets under Hernexeos brand, rovadicitinib tablet under Anxu brand,rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anqixin. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH3906; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD208. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Sino Biopharmaceutical Limited management
10- Ms. Y. Y. TseExecutive Chairwoman of the Board · born 1992
- Mr. S. Y. TseCEO & Executive Director · born 1996
- Mr. Ping TseFounder & Senior Executive Vice Chairman · born 1952
- Ms. Cheung Ling ChengExecutive Vice Chairwoman of the Board · born 1964
- Mr. Hsin TseSenior VP & Executive Director · born 1970
- Mr. Song JinVice President of Public Affairs & ESG · born 1976
- Ms. Xiaoyan Kang M.D.Chief Medical Officer · born 1976
- Dr. Meng Liu M.D., Ph.D.Head of Clinical Development for Chronic Diseases
- Dr. Rongjun Liu Ph.D.Head of Clinical Development for Autoimmune Diseases
- Ms. Kuen LaiCompany Secretary